HLA-G as a target molecule in specific immunotherapy against renal cell carcinoma

  • Authors:
    • Yoshihiro Komohara
    • Mamoru Harada
    • Yuki Ishihara
    • Shigetaka Suekane
    • Masanori Noguchi
    • Akira Yamada
    • Kei Matsuoka
    • Kyogo Itoh
  • View Affiliations

  • Published online on: December 1, 2007     https://doi.org/10.3892/or.18.6.1463
  • Pages: 1463-1468
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The human leukocyte antigen (HLA)-G molecule can exert immunoregulatory functions. However, its limited tissue distribution and preferential expression in a variety of malignancies suggest the possibility that it could be a target in anti-cancer immunotherapy. In the present study, we tested this possibility by focusing on renal cell carcinoma (RCC) patients, especially those with HLA-A24 alleles. Four HLA-G-derived peptides were prepared based on the binding motif to the HLA-A24 alleles. After a stabilization assay confirmed the binding of these peptides to HLA-A24 molecules, they were screened for the capacity to induce peptide-specific cytotoxic T lymphocytes (CTLs) from peripheral blood mononuclear cells (PBMCs) of HLA-A24+ RCC cancer patients. As a result, the HLA-G146-154 peptide was found to effectively induce peptide-specific CTLs, and HLA-G146-154 peptide-stimulated PBMCs exhibited cytotoxic activity against HLA-G-expressing HLA-A24+ RCC cells. Antibody blocking and cold inhibition experiments confirmed that the cytotoxicity was partially ascribed to peptide-specific and HLA class I-restricted CD8+ T cells. These results indicate that HLA-G-associated immunoregulation can be overcome and that HLA-G peptide-based anti-cancer immunotherapy is feasible.

Related Articles

Journal Cover

December 2007
Volume 18 Issue 6

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Komohara Y, Harada M, Ishihara Y, Suekane S, Noguchi M, Yamada A, Matsuoka K and Itoh K: HLA-G as a target molecule in specific immunotherapy against renal cell carcinoma. Oncol Rep 18: 1463-1468, 2007
APA
Komohara, Y., Harada, M., Ishihara, Y., Suekane, S., Noguchi, M., Yamada, A. ... Itoh, K. (2007). HLA-G as a target molecule in specific immunotherapy against renal cell carcinoma. Oncology Reports, 18, 1463-1468. https://doi.org/10.3892/or.18.6.1463
MLA
Komohara, Y., Harada, M., Ishihara, Y., Suekane, S., Noguchi, M., Yamada, A., Matsuoka, K., Itoh, K."HLA-G as a target molecule in specific immunotherapy against renal cell carcinoma". Oncology Reports 18.6 (2007): 1463-1468.
Chicago
Komohara, Y., Harada, M., Ishihara, Y., Suekane, S., Noguchi, M., Yamada, A., Matsuoka, K., Itoh, K."HLA-G as a target molecule in specific immunotherapy against renal cell carcinoma". Oncology Reports 18, no. 6 (2007): 1463-1468. https://doi.org/10.3892/or.18.6.1463